RUBRACA (rucaparib) Approved for the Treatment of Advanced Ovarian Cancer, Available Immediately at Biologics, Inc.

CARY, N.C. (December 20, 2016) — Biologics, Inc. has been selected by Clovis Oncology, Inc. to be a specialty pharmacy provider in the limited distribution network for RUBRACA^TM (rucaparib).

Approved by the U.S. Food and Drug Administration (FDA) on December 19, 2016, RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Patients should be selected for therapy based on an FDA-approved companion diagnostic for RUBRACA. RUBRACA was granted Breakthrough Therapy designation and Priority Review by the FDA.

“We are honored to be included in the limited distribution network for RUBRACA,” said Brandon Tom, vice president, Biopharma Services, Biologics, Inc. “We will be able to draw on our experience in ovarian cancer care to provide high-touch clinical support and improve outcomes for this patient population.”

RUBRACA is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3. Data from two clinical trials testing the efficacy of RUBRACA in patients with advanced BRCA-mutant ovarian cancer who had progressed after two or more prior chemotherapies showed an overall Objective Response Rate (ORR) of 54% and a median duration response of 9.2 months. The ORR was similar for patients with germline BRCA-mutant ovarian cancer or somatic BRCA-mutant ovarian cancer and for patients with a BRCA1 gene mutation or BRCA2 gene mutationⁱ.

About 22,000 women are diagnosed with ovarian cancer in the U.S. each year, ranking it fifth in cancer deathsⁱ. About 25 percent of women who are diagnosed with ovarian cancer have a germline or somatic BRCA mutation, making treatments that target these mutations especially important to this unique subset of patients.

Recognized for its high-touch patient care model, Biologics’ multidisciplinary care team provides individualized care plans to address the unique clinical, financial and emotional needs of each patient.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics

Biologics, Inc. is an oncology pharmacy services company that empowers healthcare providers, payers and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk.

Biologics is part of McKesson Specialty Health, a division of McKesson Corporation, empowering the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. Our combined organization will help better support patients and expedite access to oncology therapies. For more information, visit www.McKessonspecialtyhealth.com and www.biologicsinc.com.

ⁱ http://www.businesswire.com/news/home/20160823006191/en/FDA-Accepts-Clovis-Oncology%E2%80%99s-Drug-Application-Rucaparib